$PALI Cashflow Statement | Understand Stock

$PALI

$1.20 -$0.03 (2.44%) Close

$PALI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Net Income Loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
In-process research and development
Noncash transaction costs shared with Seneca
Noncash lease expense
Gain on forgiveness of PPP loan
Accretion of debt discount and non-cash interest expense
Loss on issuance of LBS Series 1 Preferred Stock
Loss on issuance of secured debt
Depreciation
Non-cash operating lease expense
Loss on issuance of warrants
Fair value of contingent consideration obligation
Change in fair value of warrant liabilities
Change in fair value of share liability
Non-cash expense for the issuance of common stock (Note 5)
Recurring fair value measurements of liabilities
Payment of contingent consideration obligation
Issuance of common stock to vendors
Write-off of deferred equity issuance costs
Loss on disposal of property and equipment
Stock-based compensation and related charges
Other

Changes in operating assets and liabilities:
Other receivables
Prepaid and other current assets and other noncurrent assets
Accounts payable and accrued liabilities
Accrued compensation and benefits
Operating lease liabilities
Net cash used in operating activities

Cash flows from investing activities:
Cash acquired in connection with the Merger
Acquisition related costs paid
Purchases of property and equipment
Net cash used in investing activities

Cash flows from financing activities:
Payments on insurance financing debt
Proceeds from issuance of debt
Proceeds from the issuance of related party debt
Proceeds from issuance of Leading Biosciences, Inc. Series 1 Preferred Stock
Redemption of warrants
Proceeds (payments) from the redemption of warrants
Proceeds from the exercise of warrants
Payment of warrant inducement issuance costs
Payment of equity issuance costs
Payment of debt issuance costs
Proceeds from issuance of common stock under Employee Stock Purchase Plan
Shares withheld for payment of employee withholding tax liability
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of year
Cash, cash equivalents and restricted cash, end of year

Supplemental disclosures of cash flow information:
Interest paid
Operating right-of-use assets obtained in exchange for operating lease liabilities
Supplemental disclosures of non-cash investing and financing activities:
Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities
Non cash impact of exercise price reset on outstanding warrants related to down round provisions
Issuance of common stock for the cashless exercise of warrants
Deferred transaction costs in accounts payable and accrued liabilities
Issuance of common stock for settlement of trade payable
Debt issuance costs included in accounts payable
Fair value of warrants issued to placement agent
Fair value of warrants issued to underwriter agent
Equity issuance costs included in accounts payable and accrued liabilities
Warrant inducement costs included in accounts payable and accrued liabilities
Proceeds from the issuance of common stock included in other current receivables (Note 5)
Fair value of common shares to be issued included in share liability (Note 5)
Fair value of warrants issued to solicitation agent in warrant inducements (Note 5)
Fair value of warrants issued to placement agents (Note 5)
Fair value of warrants issued to representatives of underwriter
Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities
Cash receivable for exercises of warrants included in prepaid and other current assets
Transaction costs shared with Seneca
Acquisition costs related to stock issuance
Issuance of common stock to former Seneca stockholders
Conversion of LBS Series C Convertible Preferred stock into common stock
Net assets acquired in the Merger
Acquisition related vesting of RSU's assumed in the Merger
Acquisition related fair value change in warrant liability assumed in the Merger
Debt discount for issuance of warrants
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
Insurance financing arrangements included in prepaid and other assets and other noncurrent assets
Insurance financing debt included in prepaid and other current assets and other noncurrent assets
Incremental fair value of modified or exchanged warrants (Note 5)

Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:
Cash and cash equivalents
Restricted cash

Comments